**Supplementary Material**

*Supplementary Table 1. Decision data by country (sources)*

|  |  |  |
| --- | --- | --- |
| Country | Institution/Database | Data source |
| England | NICE | HTA decisions from the NICE website |
| Scotland | SMC | HTA decisions from the SMC website |
| Sweden | TLV / NLT | HTA decisions from the TLV/NLT website. Validation from the TLV team. |
| Belgium | RIZIV INAMI | HTA decisions from the INAMI database (online). Validation of the data and information on Managed Entry Agreement (MEA) from the INAMI team. |
| Portugal | INFARMED | HTA decisions from INFARMED database (online). Information on the MEA from the INFARMED team. |
| Poland | AHTAPol | Database created by AHTAPol. |
| Spain | BOTPLUS | Database created by EASP and UCLM from BOTPLUS. Validation of data by GENESIS. |
| Germany | G-BA | HTA decisions from the G-BA website. Only decisions from 2011 onwards (AMNOG) |
| France | HAS/MoH | Database created by the UPEC. |

*NICE -*National Institute for Health and Care Excellence; SMC - Scottish Medicine Consortium; TLV - The Dental and Pharmaceutical Benefits Agency, NLT - New pharmaceutical product therapies, RIZIV-INAMI - Belgium Health Insurance Agency; INFARMED - National Authority of Medicines and Health Products, IP; AHTAPol - Agency for Health Technology Assessment in Poland; EASP - Andalusian School of Public Health; UCLM - University of Castilla la Mancha; GENESIS - Spanish Society of Hospital Pharmacy; G-BA - Federal Joint Committee; AMNOG - Pharmaceuticals Market Reorganisation Act; HAS - French National Authority for Health; UPEC - University Paris-Est Créteil. *Source: created by the author*

*Supplementary Table 2. Subgroup: percentage of agreement for 80 cancer drug-indications (2002-2014) – assessed by NICE and SMC*

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Agreement in HTA decisions (assessed drugs)** | **Spain** | **Germany** | **France** | **Sweden** | **Scotland** | **Portugal** | **Poland** | **England** | **Belgium** |
| **France** | 89.83% (59) *1* | 90% (10) |  | 73.33% (30) | 29.87% (77) | 88% (25) | 19.64% (56) | 41.56% (77) | 58.82% (68) |
| **Germany** | 77.78% (9) |  |  | 60% (10) | 54.55% (11) | 100% (4) | 0% (8) | 54.55% (11) | 62.50% (8) |
| **Spain** |  |  |  | 76.92% (26) | 22.95% (61) | 81.82% (22) | 19.15% (47) | 32.79% (61) | 60.38% (53) |
| **Belgium** |  |  |  | 74.07% (27) | 39.13% (69) | 66.67% (24) | 32.69% (52) | 42.03% (69) |  |
| **England** |  |  |  | 40% (30) | 63.75% (80) | 44% (25) | 44.64% (56) |  |  |
| **Poland** |  |  |  | 16% (25) | 42.86% (56) | 33.33% (24) |  |  |  |
| **Portugal** |  |  |  | 72.22% (18) | 36% (25) |  |  |  |  |
| **Scotland** |  |  |  | 36.67% (30) |  |  |  |  |  |
| **Sweden** |  |  |  |  |  |  |  |  |  |

Notes: *1 percentage of agreed decisions and in brackets, the total number of common assessed decisions in both countries*.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **>=75%** | **High Congruence** | **>=50% & <75%** | **Medium Congruence** | **<50%** | **Low Congruence** |

*Supplementary Table 3. Subgroup: Kappa Score for 80 cancer drug-indications (2002-2014) – assessed by NICE and SMC*

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **KAPPA SCORE** | **Spain** | **Germany** | **France** | **Sweden** | **Scotland** | **Portugal** | **Poland** | **England** | **Belgium** |
| **France** | 0.2934\*\*\* | 0.0000 |  | -0.1009 | 0.0253 | 0.3644\*\*\* | 0.0210 | 0.0020 | 0.0211 |
| **Germany** | 0.0000 |  |  | 0.0000 | 0.0000 | N.A. | 0.0000 | 0.0000 | 0.0000 |
| **Spain** |  |  |  | 0.0311 | -0.0365 | 0.1619\* | 0.0078 | -0.0606 | -0.0520 |
| **Belgium** |  |  |  | 0.3483\*\*\* | 0.1127\* | 0.2700\*\* | 0.0319 | 0.0858 |  |
| **England** |  |  |  | -0.0093 | 0.4661\*\*\* | 0.0331 | 0.2022\*\*\* |  |  |
| **Poland** |  |  |  | -0.0214 | 0.0904 | 0.1616\*\* |  |  |  |
| **Portugal** |  |  |  | -0.1111 | 0.0521 |  |  |  |  |
| **Scotland** |  |  |  | -0.0270 |  |  |  |  |  |
| **Sweden** |  |  |  |  |  |  |  |  |  |

*Notes: significance levels: \*\*\* p<0.01, \*\* p<0.05, \* p<0.1*

|  |  |  |
| --- | --- | --- |
| ***McHugh Threshold*** | ***Cohen Threshold*** | ***Kappa coefficient*** |
| **No Agreement** | **No Agreement** | ≤ **0.0** |
| **None to Slight** | **0.01-0.20** |
| **Minimal Agreement** | **Fair Agreement** | **0.21 - 0.39** |
| **Weak Agreement** | **Moderate Agreement** | **0.4 - 0.59** |
| **Moderate Agreement** | **Substantial Agreement** | **0.6 - 0.79** |
| **Strong Agreement** | **Almost Perfect Agreement** | **0.8 – 0.9** |
| **Almost perfect Agreement** | **Almost Perfect Agreement** | **> 0.9** |

*Supplementary Figure 1. Acceptance, restriction and rejection rate (2002-2014)*



*Source: ADVANCE-HTA dataset, created by the author*